• Exchange: London
  • Sector: Health Care
  • Industry: Biotech & Pharma
  • Sub-Industry: Specialty Pharmaceuticals

BTG:LN

599.000 GBp 4.500 0.76%

As of 03:06:30 ET on 07/29/2014.

Snapshot for BTG PLC (BTG)

Open: 602.000 Day's Range: 598.500 - 603.500 Volume: 31,682
Previous Close: 594.500 52wk Range: 363.000 - 665.000 1-Yr Rtn: +56.98%

Stock Chart for BTG

No chart data available.
  • BTG:LN 599.000
  • 1D
  • 1M
  • 1Y
594.500
Interactive BTG Chart

Previous Close

No chart data available.
Interactive Chart
  • 1D
  • 1W
  • 1M
  • YTD
  • 1Y
  • 3Y
  • 5Y
Close:
Open:
High:
Low:
Volume:
Recently Viewed Symbols
Save as Watchlist
Saving as watchlist...

Key Statistics for BTG

Current P/E Ratio (ttm) 85.6554
Estimated P/E(03/2015) 37.6266
Relative P/E vs. UKX 4.3321
Earnings Per Share (GBP) (ttm) 0.0694
Est. EPS (GBP) (03/2015) 0.1580
Est. PEG Ratio -
Market Cap (M GBP) 2,149.66
Shares Outstanding (M) 361.59
30 Day Average Volume 548,008
Price/Book (mrq) 4.0529
Price/Sale (ttm) 7.2612
Dividend Indicated Gross Yield -%
Cash Dividend (GBp) -
Dividend Ex-Date 06/07/2000
5 Year Dividend Growth -
Next Earnings Announcement 11/12/2014
mrq = Most Recent Quarter; ttm = Trailing Twelve Months

Income Statement for BTG

  • Revenue
  • Net Income (M/GBP)
  • Profit Margin (%)

Company Profile & Key Executives for BTG

BTG plc licenses, develops and commercializes pharmaceuticals and has a pipeline of development programs targeting neurological and other disorders, including varicose veins. The Company also has a substantial and growing revenue stream of milestone payments and royalties from out-licensed products.

Louise MakinCEO/Executive DirectorRolf SoderstromCFO/Executive Director
Peter StratfordCTO:Interventional MedicineGuenter R JanhoferChief Medical Officer/Head:Dev
More Company Profile & Key Executives for BTG

Quotes delayed, except where indicated otherwise. All prices in local currency. Time is ET.

Sponsored Link
Advertisement
Advertisement
Sponsored Links
Advertisements
sec ||= nil